Equity Details
Price & Market Data
Price: $1.93
Daily Change: -$0.01 / 0.52%
Daily Range: $1.74 - $2.04
Market Cap: $124,176,744
Daily Volume: 1,215,485
Performance Metrics
1 Week: -16.06%
1 Month: 7.23%
3 Months: 22.04%
6 Months: -58.87%
1 Year: 61.30%
YTD: 57.20%
About Pyxis Oncology, Inc. (PYXS)
Financial insights into Pyxis Oncology, Inc. (PYXS). Current price: 1.93, daily change: -$0.01 / 0.52%. Market cap: 124,176,744. Performance metrics across all timeframes are updated.
Company Details
Employees: 56
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
